TScan Therapeutics’ (TCRX) Buy Rating Reaffirmed at Needham & Company LLC

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company LLC in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $11.00 target price on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 103.70% from the stock’s current price.

Several other equities research analysts have also recently commented on TCRX. Wedbush restated an “outperform” rating and issued a $10.00 target price on shares of TScan Therapeutics in a research note on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, August 13th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $12.00.

TScan Therapeutics Stock Down 5.3 %

Shares of TScan Therapeutics stock traded down $0.30 on Tuesday, hitting $5.40. The company had a trading volume of 99,615 shares, compared to its average volume of 246,889. The stock has a 50-day moving average of $5.35 and a 200-day moving average of $6.54. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.77 and a quick ratio of 7.77. TScan Therapeutics has a twelve month low of $3.73 and a twelve month high of $9.69. The firm has a market capitalization of $286.06 million, a P/E ratio of -5.14 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. The firm had revenue of $0.54 million during the quarter, compared to analysts’ expectations of $1.55 million. TScan Therapeutics had a negative return on equity of 59.83% and a negative net margin of 855.84%. Research analysts predict that TScan Therapeutics will post -1.17 earnings per share for the current year.

Insider Buying and Selling at TScan Therapeutics

In related news, Director Barbara Klencke acquired 5,000 shares of the business’s stock in a transaction dated Monday, September 23rd. The stock was bought at an average price of $5.29 per share, with a total value of $26,450.00. Following the acquisition, the director now owns 45,000 shares in the company, valued at $238,050. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Zoran Zdraveski sold 164,686 shares of TScan Therapeutics stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $5.78, for a total transaction of $951,885.08. Following the completion of the transaction, the insider now owns 4,716 shares in the company, valued at approximately $27,258.48. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Barbara Klencke acquired 5,000 shares of the company’s stock in a transaction on Monday, September 23rd. The stock was acquired at an average price of $5.29 per share, for a total transaction of $26,450.00. Following the purchase, the director now directly owns 45,000 shares of the company’s stock, valued at approximately $238,050. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 15,000 shares of company stock worth $82,550 over the last ninety days. 2.76% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP acquired a new stake in TScan Therapeutics during the 2nd quarter valued at $70,000. SG Americas Securities LLC acquired a new stake in shares of TScan Therapeutics during the 3rd quarter worth about $78,000. The Manufacturers Life Insurance Company acquired a new position in TScan Therapeutics in the 2nd quarter valued at about $90,000. Cornercap Investment Counsel Inc. bought a new position in TScan Therapeutics in the 2nd quarter valued at about $134,000. Finally, Rhumbline Advisers acquired a new stake in TScan Therapeutics during the second quarter worth approximately $274,000. 82.83% of the stock is currently owned by institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.